Galderma boosts biologics production with new Swedish licensing approvals

Image credit: Africa Studio/

Galderma has secured manufacturing license updates from the Swedish Medical Products Agency, allowing the company to continue its ambitious growth and innovation agenda.

These updates followed a stringent Good Manufacturing Practices (GMP) inspection. from Galderma Uppsala, Sweden, center of excellence, the company said in a press release.

The updated licenses authorize Galderma to manufacture and conduct bioanalytical testing of RelabotulinumtoxinA (QM1114), a next-generation liquid neuromodulator developed with Galderma’s proprietary PEARL technology.

This innovative technology maintains the integrity of the molecule, resulting in a highly active, complex-free botulinum toxin A, representing a significant advancement in injectable aesthetics.

Adrian Murphy, Head of Global Operations at Galderma, emphasized the importance of these updates: “Our commitment to leading innovation in dermatology is reflected in our high-quality operations.”

He continued: “These new license updates granted by the Swedish authorities reflect Galderma’s capabilities and the capabilities we are building to support our rapid growth trajectory.”

“As we work to extend our leadership in the category globally, these new capabilities will increase Galderma’s autonomy to produce and commercialize the next generation of scientifically differentiated innovations in dermatology.”

The Uppsala Center of Excellence is one of four state-of-the-art manufacturing and R&D facilities operated by Galderma worldwide.

The new facility is currently being expanded to meet rising global demand for science-based premium dermatology solutions and is expected to be completed by the end of 2025.

It is strategically designed to support increased demand for injectable aesthetic treatments and future product developments.

The modular design of the facility allows for seamless future expansion, in line with Galderma’s growth strategy and its Environmental, Social and Governance (ESG) roadmap.

RelabotulinumtoxinA, developed by Galderma, is a highly active, innovative, complex-free and ready-to-use liquid botulinum toxin A with a patented strain. The unique liquid formulation eliminates the need for reconstitution from powder, reducing the variability, errors and risks associated with reconstitution. This ensures better consistency of results.

Currently under investigation worldwide, RelabotulinumtoxinA aims to expand Galderma’s neuromodulator portfolio and contribute to the broadest portfolio of injectable aesthetic products on the market.

Related Posts